UM
MRNA icon

UniSuper Management’s Moderna MRNA Stock Holding History

UniSuper Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
23,601
-13,249
-36% -$685K 0.01% 456
2026
Q1 		$1.87M Sell
36,850
-21,467
-37% -$1M 0.01% 474
2025
Q4 		$1.72M Sell
58,317
-17,862
-23% -$485K 0.01% 496
2025
Q3 		$1.97M Buy
76,179
+15,330
+25% +$428K 0.01% 502
2025
Q2 		$1.68M Buy
60,849
+4,993
+9% +$131K 0.01% 520
2025
Q1 		$1.58M Buy
55,856
+4,903
+10% +$174K 0.01% 518
2024
Q4 		$2.12M Buy
50,953
+20,862
+69% +$997K 0.02% 440
2024
Q3 		$2.01M Buy
30,091
+10,328
+52% +$948K 0.02% 436
2024
Q2 		$2.35M Buy
19,763
+6,605
+50% +$836K 0.02% 348
2024
Q1 		$1.4M Buy
13,158
+9,931
+308% +$1M 0.01% 357
2023
Q4 		$321K Sell
3,227
-1,762
-35% -$148K ﹤0.01% 417
2023
Q3 		$515K Sell
4,989
-556
-10% -$62K 0.01% 319
2023
Q2 		$674K Buy
+5,545
New +$740K 0.01% 292

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

UniSuper Management's MRNA Position: Q2 2026 in Review

UniSuper Management reduced its Moderna (MRNA) stake by 36% in Q2 2026, selling an estimated $685K and leaving 23,601 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #456.

UniSuper Management first reported a position in MRNA in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.35M in Q2 2024. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • UniSuper Management held 23,601 shares of Moderna worth $1.65M as of Q2 2026.
  • UniSuper Management sold 13,249 Moderna shares in Q2 2026, an estimated $685K.
  • Moderna made up 0.01% of UniSuper Management's portfolio in Q2 2026, its #456 holding.
  • UniSuper Management first reported a position in Moderna in Q2 2023 and has held it in 13 quarters since.
  • UniSuper Management's Moderna position peaked at $2.35M in Q2 2024.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.